Trump’s New Decision: Trump announced 200 percent tariff on these medicines, Indian pharmaceutical companies may get a big blow!

New Delhi. A new decision by US President Donald Trump may now have a heavy impact on India’s generic drug industry. Trump said on Wednesday that tariffs will be imposed on generic drugs imported from August 2028. Generic products of Indian pharmaceutical companies go to America in large numbers. Due to Trump’s decision to impose heavy tariffs, the generic medicines manufactured by them are likely to become very expensive. Trump has written on social media that from August 1, 2026, there will be no tariff on generic medicines coming to America for the next two years. Trump has said that there will be 100 percent tariff on generic drugs for one year from 2028. After which it will be increased to 200 percent.

Trump has said that the decision to impose heavy tariffs on generic medicines was taken so that the companies manufacturing them could set up plants in America. Trump said that fines will also be imposed on companies that do not install plants and equipment to make generic drugs within the stipulated time. Trump has linked the reason for tariff on generic medicines to the safety of American citizens. He also said that his policy on patented, branded and innovative medicines has been successful and will continue to be so. Trump has imposed 100 percent tariff on the import of such medicines. Trump’s imposition of heavy tariffs on generic medicines will increase problems for Indian pharmaceutical companies. According to a report, last year India had exported medicines worth $9.7 billion to America. India is a major manufacturer of generic medicines and by 2025 it has exported medicines worth $25.8 billion worldwide.

People in America buy generic medicines made in India for blood pressure, diabetes, cancer, mental health and other diseases. Trump’s 200 percent tariff will also increase the prices of these generic medicines in India. For example, if a generic medicine is currently available for $2, its price will increase to $6 by 2029. In such a situation, to avoid tariffs, Indian pharmaceutical companies will have to set up plants in America. This will impact India also and the export of generic medicines to America will reduce. Last year, India exported 38 percent of its total pharmaceutical exports to America.